
Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.

DXN's share price surged from 2 cents to 14 cents in 2026 after winning major AI and telecommunications infrastructure contracts. The modular data centre specialist is expanding globally, with investors betting on strong growth from AI, cloud, and digital infrastructure markets.

VEEM shares jumped nearly 19% after completing a major factory expansion. The advanced engineering company is growing its marine, defence, and gyrostabiliser businesses through new products, defence contracts, AUKUS-related opportunities, and increased manufacturing capacity to support future earnings growth.

Genesis Minerals (ASX: GMD) is accelerating production, generating exceptional cash flow, and advancing its Tower Hill growth engine while the stock approaches key breakout levels. We assess fundamentals, catalysts, risks, and technical signals.

Zip Co is recovering from 2026 lows on record earnings, a buyback, and US growth via Stripe. Technically, it broke a downtrend with support near $2.00. Key risks: credit quality, US concentration, and competition.

Bellevue Gold (ASX: BGL) is lifting production, lowering costs, and generating record free cash flow as higher grade zones come online and hedge commitments fall, positioning the company for a multi year re rating.